Machado-Joseph Disease / Spinocerebellar Ataxia Type 3

Motility Profile of Captive-Bred Marmosets Revealed by a Long-Term In-Cage Monitoring System

“…For Experiment 2, three marmosets (three males, aged 184 ± 1.4 days) were recruited from the polyglutamine disease model transgenic marmoset line (second generation) recently established in our laboratory (Tomioka et al, 2017). Polyglutamine diseases are heritable neurodegenerative disorders caused by expansion of trinucleotide repeats for the polyglutamine tract (Nóbrega and De Almeida, 2012). This animal model typically shows a variety of motor disease symptoms characterized by progressively lower daily activity (Tomioka et al, 2017).…”

“…Motility declines following functional deterioration of multiple body parts (Ferrucci et al, 2016;Buchman et al, 2018). Movement disorder often accompanies certain neurologic diseases (Taroni and Didonato, 2004;Nóbrega and De Almeida, 2012), severely limiting an individual's viability (Barlow et al, 1996;Robinson et al, 2013). Behavioral phenotyping of experimental animal models of human disease aims to quantitatively characterize the motor behavior and its disease-specific deviation from healthy animals (Lin et al, 2001;Pratte et al, 2011;Urbach et al, 2014).…”

Motility Profile of Captive-Bred Marmosets Revealed by a Long-Term In-Cage Monitoring System

“…For Experiment 2, three marmosets (three males, aged 184 ± 1.4 days) were recruited from the polyglutamine disease model transgenic marmoset line (second generation) recently established in our laboratory (Tomioka et al, 2017). Polyglutamine diseases are heritable neurodegenerative disorders caused by expansion of trinucleotide repeats for the polyglutamine tract (Nóbrega and De Almeida, 2012). This animal model typically shows a variety of motor disease symptoms characterized by progressively lower daily activity (Tomioka et al, 2017).…”

“…Motility declines following functional deterioration of multiple body parts (Ferrucci et al, 2016;Buchman et al, 2018). Movement disorder often accompanies certain neurologic diseases (Taroni and Didonato, 2004;Nóbrega and De Almeida, 2012), severely limiting an individual's viability (Barlow et al, 1996;Robinson et al, 2013). Behavioral phenotyping of experimental animal models of human disease aims to quantitatively characterize the motor behavior and its disease-specific deviation from healthy animals (Lin et al, 2001;Pratte et al, 2011;Urbach et al, 2014).…”

Motility Profile of Captive-Bred Marmosets Revealed by a Long-Term In-Cage Monitoring System

“…For Experiment 2, three marmosets (three males, aged 184 ± 1.4 days) were recruited from the polyglutamine disease model transgenic marmoset line (second generation) recently established in our laboratory (Tomioka et al, 2017). Polyglutamine diseases are heritable neurodegenerative disorders caused by expansion of trinucleotide repeats for the polyglutamine tract (Nóbrega and De Almeida, 2012). This animal model typically shows a variety of motor disease symptoms characterized by progressively lower daily activity (Tomioka et al, 2017).…”

“…Motility declines following functional deterioration of multiple body parts (Ferrucci et al, 2016;Buchman et al, 2018). Movement disorder often accompanies certain neurologic diseases (Taroni and Didonato, 2004;Nóbrega and De Almeida, 2012), severely limiting an individual's viability (Barlow et al, 1996;Robinson et al, 2013). Behavioral phenotyping of experimental animal models of human disease aims to quantitatively characterize the motor behavior and its disease-specific deviation from healthy animals (Lin et al, 2001;Pratte et al, 2011;Urbach et al, 2014).…”

Motility Profile of Captive-Bred Marmosets Revealed by a Long-Term In-Cage Monitoring System

“…For Experiment 2, three marmosets (three males, aged 184 ± 1.4 days) were recruited from the polyglutamine disease model transgenic marmoset line (second generation) recently established in our laboratory (Tomioka et al, 2017). Polyglutamine diseases are heritable neurodegenerative disorders caused by expansion of trinucleotide repeats for the polyglutamine tract (Nóbrega and De Almeida, 2012). This animal model typically shows a variety of motor disease symptoms characterized by progressively lower daily activity (Tomioka et al, 2017).…”

“…Motility declines following functional deterioration of multiple body parts (Ferrucci et al, 2016;Buchman et al, 2018). Movement disorder often accompanies certain neurologic diseases (Taroni and Didonato, 2004;Nóbrega and De Almeida, 2012), severely limiting an individual's viability (Barlow et al, 1996;Robinson et al, 2013). Behavioral phenotyping of experimental animal models of human disease aims to quantitatively characterize the motor behavior and its disease-specific deviation from healthy animals (Lin et al, 2001;Pratte et al, 2011;Urbach et al, 2014).…”